Loading...
XSHE002365
Market cap326mUSD
Dec 27, Last price  
8.17CNY
1D
1.87%
1Q
7.78%
Jan 2017
-51.08%
IPO
-44.23%
Name

Qianjiang Yongan Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XSHE:002365 chart
P/E
—
P/S
2.45
EPS
—
Div Yield, %
1.24%
Shrs. gr., 5y
0.33%
Rev. gr., 5y
-0.66%
Revenues
973m
-33.48%
156,704,175314,987,987447,487,684310,299,295319,729,297417,014,860470,697,829522,718,155658,417,064555,893,651549,399,724932,771,7281,005,407,8321,370,443,0521,172,853,5191,565,409,1811,462,447,548972,890,144
Net income
-12m
L
37,461,90568,949,410102,583,75165,052,74846,106,94069,768,15575,356,02923,006,61231,722,30517,612,60362,297,040133,150,739178,584,28489,932,157105,559,791111,416,036140,349,121-12,312,563
CFO
244m
-36.93%
061,079,336158,468,03336,429,21944,063,52591,229,95270,749,51163,648,21819,263,27170,606,59584,534,206197,318,497314,023,302239,545,250206,662,267101,810,834387,279,801244,257,079
Dividend
Jul 05, 20240.1 CNY/sh
Earnings
Jun 20, 2025

Profile

Qianjiang Yongan Pharmaceutical Co., Ltd. manufactures and sells taurine in China. The company was founded in 2001 and is based in Qianjiang, China.
URL
http://www.chinataurine.com/
IPO date
Mar 05, 2010
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
972,890
-33.48%
1,462,448
-6.58%
1,565,409
33.47%
Cost of revenue
887,250
1,234,940
1,365,753
Unusual Expense (Income)
NOPBT
85,640
227,507
199,656
NOPBT Margin
8.80%
15.56%
12.75%
Operating Taxes
34,466
20,341
10,805
Tax Rate
40.25%
8.94%
5.41%
NOPAT
51,174
207,167
188,851
Net income
(12,313)
-108.77%
140,349
25.97%
111,416
5.55%
Dividends
(29,468)
(29,428)
Dividend yield
1.02%
0.94%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
10,015
40,014
20,380
Long-term debt
Deferred revenue
11,307
13,051
Other long-term liabilities
8,501
1
1
Net debt
(1,014,556)
(792,205)
(527,149)
Cash flow
Cash from operating activities
244,257
387,280
101,811
CAPEX
(120,741)
Cash from investing activities
(166,049)
21,827
Cash from financing activities
(65,772)
17,813
FCF
203,780
300,341
36,043
Balance
Cash
956,271
832,219
547,529
Long term investments
68,300
Excess cash
975,927
759,097
469,258
Stockholders' equity
1,335,513
1,390,228
1,244,799
Invested Capital
1,090,879
1,390,294
1,515,653
ROIC
4.12%
14.26%
13.63%
ROCE
4.08%
10.46%
9.95%
EV
Common stock shares outstanding
294,682
294,682
294,682
Price
9.78
-6.86%
10.50
-1.04%
10.61
13.11%
Market cap
2,881,995
-6.86%
3,094,166
-1.04%
3,126,581
15.53%
EV
1,931,816
2,387,591
2,690,492
EBITDA
220,822
351,131
315,616
EV/EBITDA
8.75
6.80
8.52
Interest
627
664
2,441
Interest/NOPBT
0.73%
0.29%
1.22%